These results provide a rationale for meningioma treatment in accordance with PSMA expression and call for clinical trial testing utilizing PSMA-targeted therapies as alternative diagnostic, therapeutic, and maintenance approaches for recurrent/refractory meningiomas. The gene discussed is FOLH1; the disease is meningioma.